AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab

Alojzija Hočevar; Boris Lestan; Snežna Sodin Šemrl; Katja Lakota; Nika Kojc; Nataša Potočnik; Matija Tomšič

doi:10.3109/13506129.2013.838947

AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab

Amyloid. 2013 Dec;20(4):275-6. doi: 10.3109/13506129.2013.838947. Epub 2013 Oct 9.

Authors

Alojzija Hočevar¹, Boris Lestan, Snežna Sodin Šemrl, Katja Lakota, Nika Kojc, Nataša Potočnik, Matija Tomšič

Affiliation

¹ Department of Rheumatology, University Medical Centre Ljubljana , Ljubljana , Slovenia .

PMID: 24106820
DOI: 10.3109/13506129.2013.838947

Abstract

Amyloid A (AA) (secondary) amyloidosis represents a severe complication of chronic inflammatory diseases. Since pathogenic mechanisms point to the central role of interleukin 6 (IL-6) in the process of amyloid AA generation, IL-6 blockade seems an attractive therapeutic option. We report a case of a patient with polyarteritis nodosa complicated by AA amyloidosis treated with tocilizumab.

Publication types

Case Reports

MeSH terms

Adult
Amyloidosis / drug therapy*
Amyloidosis / metabolism
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Methylprednisolone / administration & dosage
Methylprednisolone / therapeutic use
Polyarteritis Nodosa / drug therapy*
Polyarteritis Nodosa / metabolism
Serum Amyloid A Protein / metabolism

Substances

Antibodies, Monoclonal, Humanized
Serum Amyloid A Protein
tocilizumab
Methylprednisolone